OncoMatch/Clinical Trials/NCT06178198
Radiation Major Hepatectomy to Selectively Treat Large Unifocal Hepatocellular Carcinoma
Is NCT06178198 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for hepatocellular carcinoma.
The RESCUE trial is a prospective, single-arm clinical study to evaluate the efficacy and safety of ablative radioembolization using Yttrium-90. This treatment is being investigated as a potential curative approach, as well as a bridging or downstaging strategy for surgery, in patients with large hepatocellular carcinoma (greater than 8 cm) who maintain good liver function.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
Leukocytes ≥ 2,500/µL and ≤ 12,000/µL; Absolute neutrophil count ≥ 1,500 /mm^3; Hemoglobin ≥ 8.0 g/dL (transfusion allowed); Platelet ≥ 50,000/µL
Kidney function
Creatinine ≤ 2.0 mg/dL
Liver function
Total bilirubin ≤ 3.0 mg/dL; AST ≤ 200 IU/L (≤ 5X ULN); ALT ≤ 200 IU/L (≤ 5X ULN); ALP ≤ 575 IU/L (≤ 5X ULN); INR ≤ 2.0 for patients not taking anticoagulants; Child-Pugh class A
Patients with no major organ dysfunction according to blood tests performed within one month of study enrollment. 1. Leukocytes ≥ 2,500/µL and ≤ 12,000/µL 2. Absolute neutrophil count ≥ 1,500 /mm^3 3. Hemoglobin ≥ 8.0 g/dL (transfusion allowed to meet this criterion) 4. Total bilirubin ≤ 3.0 mg/dL 5. Platelet ≥ 50,000/µL 6. INR ≤ 2.0 for patients not taking anticoagulants 7. AST ≤ 200 IU/L (i.e., ≤ 5X upper normal limit) 8. ALT ≤ 200 IU/L (i.e., ≤ 5X upper normal limit) 9. ALP ≤ 575 IU/L (i.e., ≤ 5X upper normal limit) 10. Creatinine ≤ 2.0 mg/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify